




The relative strengths and weaknesses of Oncternal Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncternal Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 22% points. The greatest weakness of Oncternal Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is 109%, being 134% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	15,171
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,567
Liabilities, Non-Current	0
Other Assets	322
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,488
Other Revenues	0
Property and Equipment	112
Research and Development	32,318
Selling, General and Administrative Expense	11,281

Output Variable	Value in 1000 USD
Assets	15,605
Liabilities	4,567
Expenses	43,599
Revenues	0
Stockholders Equity	11,038
Net Income	-42,111
Comprehensive Net Income	-42,111
BaseVar	32,630
ECR before LimitedLiability	-179%
Economic Capital Ratio	109%